Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma
Open Access
- 3 March 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5), 2538
- https://doi.org/10.3390/ijms22052538
Abstract
Heat shock protein 90 (HSP90) plays an essential role in lung adenocarcinoma, acting as a key chaperone involved in the correct functioning of numerous highly relevant protein drivers of this disease. To this end, HSP90 inhibitors have emerged as promising therapeutic strategies, even though responses to them have been limited to date. Given the need to maximize treatment efficacy, the objective of this study was to use isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic techniques to identify proteins in human lung adenocarcinoma cell lines whose basal abundances were correlated with response to HSP90 inhibitors (geldanamycin and radicicol derivatives). From the protein profiles identified according to response, the relationship between lactate dehydrogenase B (LDHB) and DNA topoisomerase 1 (TOP1) with respect to sensitivity and resistance, respectively, to geldanamycin derivatives is noteworthy. Likewise, rhotekin (RTKN) and decaprenyl diphosphate synthase subunit 2 (PDSS2) were correlated with sensitivity and resistance to radicicol derivatives. We also identified a relationship between resistance to HSP90 inhibition and the p53 pathway by glucose deprivation. In contrast, arginine biosynthesis was correlated with sensitivity to HSP90 inhibitors. Further study of these outcomes could enable the development of strategies to improve the clinical efficacy of HSP90 inhibition in patients with lung adenocarcinoma.Funding Information
- Comunidad de Madrid (B2017/BMD3884)
- Instituto de Salud Carlos III (PIE15/00076, PI17/00778, DTS17/00089, PI20/00820, AC20/00070,CB16/12/00442, PI17/00033 , PI20/01109, PI16/01311 and PI19/00320)
- Fundación Mutua Madrileña (2014)
- Ministry of Health and Social Welfare of the Junta de Andalucía (Nicolas Monardes Program RC-0004-2020 and OH-0022-2018)
- Fundación Científica Asociación Española Contra el Cáncer (AIO2015)
This publication has 66 references indexed in Scilit:
- Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsInvestigational New Drugs, 2012
- Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?Clinical Cancer Research, 2012
- An Interaction Network Predicted from Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone MachinePLOS ONE, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- SMARCA5Methylation and Expression in Gastric CancerCancer Investigation, 2011
- Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligaseProceedings of the National Academy of Sciences of the United States of America, 2009
- Glucose deprivation-induced metabolic oxidative stress and cancer therapyJournal of Cancer Research and Therapeutics, 2009
- Integration of Gene Dosage and Gene Expression in Non-Small Cell Lung Cancer, Identification of HSP90 as Potential TargetPLOS ONE, 2008
- Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibitionBritish Journal of Cancer, 2007
- Leigh Syndrome with Nephropathy and CoQ10 Deficiency Due to decaprenyl diphosphate synthase subunit 2 (PDSS2) MutationsAmerican Journal of Human Genetics, 2006